These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3064359)

  • 1. Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease.
    Adány R; Szegedi A; Ablin RJ; Muszbek L
    Thromb Haemost; 1988 Oct; 60(2):293-7. PubMed ID: 3064359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrin deposits in Hodgkin's disease.
    Harris NL; Dvorak AM; Smith J; Dvorak HF
    Am J Pathol; 1982 Jul; 108(1):119-29. PubMed ID: 7046453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen deposition and macrophage-associated fibrin formation in malignant and nonmalignant lymphoid tissue.
    Costantini V; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
    J Lab Clin Med; 1992 Feb; 119(2):124-31. PubMed ID: 1740624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx.
    Bárdos H; Juhász A; Répássy G; Adány R
    Thromb Haemost; 1998 Nov; 80(5):767-72. PubMed ID: 9843169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrin deposition in primary and metastatic human brain tumours.
    Bárdos H; Molnár P; Csécsei G; Adány R
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):536-48. PubMed ID: 8874864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
    Sakata Y; Aoki N
    J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets.
    Hevessy Z; Haramura G; Boda Z; Udvardy M; Muszbek L
    Thromb Haemost; 1996 Jan; 75(1):161-7. PubMed ID: 8713796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of factor XIII containing-macrophages in lymph nodes with Hodgkin's disease.
    Adány R; Nemes Z; Muszbek L
    Br J Cancer; 1987 Apr; 55(4):421-6. PubMed ID: 3555591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis.
    Carmassi F; de Negri F; Morale M; Song KY; Chung SI
    Semin Thromb Hemost; 1996; 22(6):489-96. PubMed ID: 9122713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
    Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M
    J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
    van Giezen JJ; Minkema J; Bouma BN; Jansen JW
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):869-75. PubMed ID: 7511944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
    Dewerchin M; Collen D; Lijnen HR
    Thromb Haemost; 2001 Aug; 86(2):640-6. PubMed ID: 11522016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular activation in the histopathogenesis of Hodgkin's disease: potential role of endothelial tissue factor in intravascular thrombosis and necrosis.
    Ruco LP; Pittiglio M; Dejana E; Baroni CD
    J Pathol; 1993 Oct; 171(2):131-6. PubMed ID: 7506770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas.
    Dorfman DM; Shahsafaei A
    Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.